Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance
Since 2017, targeted therapies combined with conventional intensive chemotherapy have started to improve outcome of patients with acute myeloid leukemia (AML). However, even before these innovations outcomes with intensive chemotherapy have improved, which has not yet been extensively studied. Thus...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2024-11-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/11814 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850199154613026816 |
|---|---|
| author | Marta Anna Sobas Amin T. Turki Angela Villaverde Ramiro Alberto Hernández Sánchez Javier Martinez Elicegui Teresa González Raúl Azibeiro Melchor María Abáigar Laura Tur Daniele Dall'Olio Eric Sträng Jesse M. Tettero Gastone Castellani Axel Benner Konstanze Döhner Christian Thiede Klaus H. Metzeler Torsten Haferlach Frederik Damm Rosa Ayala Joaquín Martínez-López Ken I Mills Jorge Sierra Sören Lehmann Matteo G. Della Porta Jiri Mayer Dirk Reinhardt Rubén Villoria Medina Renate Schulze-Rath Martje Barbus Jesús María Hernández-Rivas Brian J.P Huntly Gert Ossenkoppele Hartmut Döhner Lars Bullinger |
| author_facet | Marta Anna Sobas Amin T. Turki Angela Villaverde Ramiro Alberto Hernández Sánchez Javier Martinez Elicegui Teresa González Raúl Azibeiro Melchor María Abáigar Laura Tur Daniele Dall'Olio Eric Sträng Jesse M. Tettero Gastone Castellani Axel Benner Konstanze Döhner Christian Thiede Klaus H. Metzeler Torsten Haferlach Frederik Damm Rosa Ayala Joaquín Martínez-López Ken I Mills Jorge Sierra Sören Lehmann Matteo G. Della Porta Jiri Mayer Dirk Reinhardt Rubén Villoria Medina Renate Schulze-Rath Martje Barbus Jesús María Hernández-Rivas Brian J.P Huntly Gert Ossenkoppele Hartmut Döhner Lars Bullinger |
| author_sort | Marta Anna Sobas |
| collection | DOAJ |
| description |
Since 2017, targeted therapies combined with conventional intensive chemotherapy have started to improve outcome of patients with acute myeloid leukemia (AML). However, even before these innovations outcomes with intensive chemotherapy have improved, which has not yet been extensively studied. Thus, we used a large pan-European multicenter dataset of the HARMONY Alliance to evaluate treatment-time dependent outcomes over two decades. In 5359 AML patients, we compared the impact of intensive induction therapy on outcome over four consecutive 5-year calendar periods from 1997 to 2016. During that time, the 5- year survival of AML patients improved significantly, also across different genetic risk groups. In particular, the 60-day mortality rate has dropped from 13.0% to 4.7% over time. The independent effect of calendar periods on outcome was confirmed in multivariate models. Improvements were documented both for patients |
| format | Article |
| id | doaj-art-89bacc8433e84280a3c6e07ffa0f97ee |
| institution | OA Journals |
| issn | 0390-6078 1592-8721 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Ferrata Storti Foundation |
| record_format | Article |
| series | Haematologica |
| spelling | doaj-art-89bacc8433e84280a3c6e07ffa0f97ee2025-08-20T02:12:41ZengFerrata Storti FoundationHaematologica0390-60781592-87212024-11-01999110.3324/haematol.2024.285805Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY AllianceMarta Anna Sobas0Amin T. Turki1Angela Villaverde Ramiro2Alberto Hernández Sánchez3Javier Martinez Elicegui4Teresa González5Raúl Azibeiro Melchor6María Abáigar7Laura Tur8Daniele Dall'Olio9Eric Sträng10Jesse M. Tettero11Gastone Castellani12Axel Benner13Konstanze Döhner14Christian Thiede15Klaus H. Metzeler16Torsten Haferlach17Frederik Damm18Rosa Ayala19Joaquín Martínez-López20Ken I Mills21Jorge Sierra22Sören Lehmann23Matteo G. Della Porta24Jiri Mayer25Dirk Reinhardt26Rubén Villoria Medina27Renate Schulze-Rath28Martje Barbus29Jesús María Hernández-Rivas30Brian J.P Huntly31Gert Ossenkoppele32Hartmut Döhner33Lars Bullinger34Department of Hematology, Blood Neoplasm and Bone Marrow Transplantation, Wroclaw Medical UniversityDepartment of Hematology and Oncology, Marienhospital University Hospital, Ruhr-University Bochum, BochumInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Cancer Research Center of Salamanca (USAL-CSIC), SalamancaInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Cancer Research Center of Salamanca (USAL-CSIC), Salamanca, Spain; Hematology Department, University Hospital of Salamanca, SalamancaInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Cancer Research Center of Salamanca (USAL-CSIC), SalamancaInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Cancer Research Center of Salamanca (USAL-CSIC), SalamancaHematology Department, University Hospital of Salamanca, SalamancaInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Cancer Research Center of Salamanca (USAL-CSIC), SalamancaGMV Innovating Solutions, ValenciaIRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, ItaliaDepartment of Hematology, Oncology and Cancer Immunology, Campus Virchow, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, BerlinDepartment of Hematology, Amsterdam University Medical Center location Vrije Universiteit Amsterdam, Amsterdam, NetherlandsDepartment of Medical and Surgical Sciences - DIMEC, University of Bologna, BolognaDivision of Biostatistics, German Cancer Research Center (DKFZ), HeidelbergDepartment of Internal Medicine III, University Hospital Ulm, UlmDepartment of Internal Medicine I, University Hospital Dresden, DresdenDepartment for Hematology, Cell Therapy and Hemostaseology, University of Leipzig Medical Center, LeipzigMLL Munich Leukemia Laboratory, MunichDepartment of Hematology, Oncology and Cancer Immunology, Campus Virchow, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), HeidelbergHematology Department, Hospital Universitario 12 de Octubre, Complutense University CNIO MadridHematology Department, Hospital Universitario 12 de Octubre, Complutense University CNIO MadridPatrick G Johnston Centre for Cancer Research, Queen's University Belfast, BelfastHospital Santa Creu Sant Pau, BarcelonaUppsala University Hospital, UppsalaIRCCS Humanitas Research Hospital, via Manzoni 56, 20089 Rozzano, Milan, Italy; and Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, MilanDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk UniversityDepartment of Pediatrics III, University Hospital Essen, University Duisburg-Essen, EssenGMV Innovating Solutions, ValenciaBayer AG, Pharmaceuticals Division, BerlinAbbVie Deutschland GmbH and Co KG, WiesbadenInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Hematology Department, University Hospital of Salamanca, SalamancaDepartment of Haematology and Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, CambridgeCenter, Amsterdam UMC,location VUMC, NetherlandsDepartment of Internal Medicine III, University Hospital Ulm, UlmDepartment of Hematology, Oncology and Cancer Immunology, Campus Virchow, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg Since 2017, targeted therapies combined with conventional intensive chemotherapy have started to improve outcome of patients with acute myeloid leukemia (AML). However, even before these innovations outcomes with intensive chemotherapy have improved, which has not yet been extensively studied. Thus, we used a large pan-European multicenter dataset of the HARMONY Alliance to evaluate treatment-time dependent outcomes over two decades. In 5359 AML patients, we compared the impact of intensive induction therapy on outcome over four consecutive 5-year calendar periods from 1997 to 2016. During that time, the 5- year survival of AML patients improved significantly, also across different genetic risk groups. In particular, the 60-day mortality rate has dropped from 13.0% to 4.7% over time. The independent effect of calendar periods on outcome was confirmed in multivariate models. Improvements were documented both for patients https://haematologica.org/article/view/11814 |
| spellingShingle | Marta Anna Sobas Amin T. Turki Angela Villaverde Ramiro Alberto Hernández Sánchez Javier Martinez Elicegui Teresa González Raúl Azibeiro Melchor María Abáigar Laura Tur Daniele Dall'Olio Eric Sträng Jesse M. Tettero Gastone Castellani Axel Benner Konstanze Döhner Christian Thiede Klaus H. Metzeler Torsten Haferlach Frederik Damm Rosa Ayala Joaquín Martínez-López Ken I Mills Jorge Sierra Sören Lehmann Matteo G. Della Porta Jiri Mayer Dirk Reinhardt Rubén Villoria Medina Renate Schulze-Rath Martje Barbus Jesús María Hernández-Rivas Brian J.P Huntly Gert Ossenkoppele Hartmut Döhner Lars Bullinger Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance Haematologica |
| title | Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance |
| title_full | Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance |
| title_fullStr | Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance |
| title_full_unstemmed | Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance |
| title_short | Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance |
| title_sort | outcomes with intensive treatment for acute myeloid leukemia an analysis of two decades of data from the harmony alliance |
| url | https://haematologica.org/article/view/11814 |
| work_keys_str_mv | AT martaannasobas outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT amintturki outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT angelavillaverderamiro outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT albertohernandezsanchez outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT javiermartinezelicegui outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT teresagonzalez outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT raulazibeiromelchor outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT mariaabaigar outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT lauratur outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT danieledallolio outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT ericstrang outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT jessemtettero outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT gastonecastellani outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT axelbenner outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT konstanzedohner outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT christianthiede outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT klaushmetzeler outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT torstenhaferlach outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT frederikdamm outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT rosaayala outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT joaquinmartinezlopez outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT kenimills outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT jorgesierra outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT sorenlehmann outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT matteogdellaporta outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT jirimayer outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT dirkreinhardt outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT rubenvilloriamedina outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT renateschulzerath outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT martjebarbus outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT jesusmariahernandezrivas outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT brianjphuntly outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT gertossenkoppele outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT hartmutdohner outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance AT larsbullinger outcomeswithintensivetreatmentforacutemyeloidleukemiaananalysisoftwodecadesofdatafromtheharmonyalliance |